SUBSCRIBE
SUBSCRIBE
News   Drug Development

European Commission Awards Orphan Designation to Knopp NeuroSciences’ KNS-760704 in ALS

March 10, 2009 | 
1 min read
PITTSBURGH--(BUSINESS WIRE)--Knopp Neurosciences Inc. (“Knopp”) today announced that the European Commission (“EC”) has designated KNS-760704 as an orphan medicinal product for the treatment of Amyotrophic Lateral Sclerosis.
Clinical research Phase II
MORE ON THIS TOPIC
AbbVie's office in South San Francisco, California
Cancer
AbbVie Scoops Up Ichnos Glenmark’s Lead Myeloma Antibody for Nearly $2B
July 10, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
Business consultant. Hands help a businessman is falling from a graph vector
Rare diseases
Ultragenyx, Mereo Plummet After Late-Stage Trial for Rare Genetic Disorder Appears To Fall Short
July 10, 2025
 · 
2 min read
 · 
Tristan Manalac
FDA signage at its headquarters in Maryland
ALS
ALS Community Petitions FDA To Reconsider BrainStorm’s NurOwn, Pointing to Recent Survival Data
July 8, 2025
 · 
3 min read
 · 
Heather McKenzie
Yellow Forklift truck truckraises a box over a stack of boxes and red arrow down. Decrease in economic rates, low demand for goods, decrease in import or export. Reduced storage, logistics costs
Immunology and inflammation
Jasper Crashes as Compromised Drug Lot Confounds Urticaria Study
July 8, 2025
 · 
2 min read
 · 
Tristan Manalac